Law360, New York (July 7, 2017, 5:49 PM EDT) -- A Pennsylvania federal judge on Friday ended Canadian pharmaceutical company Apotex’s pay-for-delay suit accusing generic-drug maker Ranbaxy of violating antitrust laws by accepting a settlement with Cephalon that improperly delayed generic alternatives to the narcolepsy medication Provigil from entry into the market.
U.S. District Judge Mitchell S. Goldberg said counsel for Apotex Inc. and Ranbaxy Laboratories Ltd. reached an undisclosed settlement to end the suit.
The decade-old antitrust litigation stems from a series of reverse-payment settlements worth about $300 million that Cephalon inked with Ranbaxy and...
Apotex, Ranbaxy End Pay-For-Delay Suit Over Narcolepsy Med
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
